15 Low Profile Dividend Champions to Buy

4. West Pharmaceutical Services, Inc. (NYSE:WST)

Number of Hedge Fund Holders: 35

West Pharmaceutical Services, Inc. (NYSE:WST) develops and sells products used in pharmaceuticals, biologics, vaccines, and consumer healthcare. In its latest earnings report, the company noted that its core operations continue to thrive, supported by its strong market positions and proprietary processes. Looking ahead to 2025, management expressed confidence in continued momentum within key segments of the Proprietary Products business, citing positive trends in High-Value Products (HVP) across Biologics and Generics, along with growth stemming from Annex 1 and GLP-1 developments.

In the fourth quarter of 2024, West Pharmaceutical Services, Inc. (NYSE:WST) reported revenue of $748.8 million, which showed a 2.3% growth from the same period last year. The revenue surpassed analysts’ estimates by nearly $8 million. Organic net sales rose by 4.5%, with High-Value Products (HVP) accounting for around 74% of the segment’s total sales during the period. This was largely driven by strong demand for self-injection device platforms. Additionally, fourth-quarter revenue received a roughly $25 million boost from customer incentives tied to volume targets met for HVP delivery devices.

West Pharmaceutical Services, Inc. (NYSE:WST)’s cash flow for the year came in at $653.4 million, and its free cash flow amounted to $276.4 million. The company’s quarterly dividend currently sits at $0.21 per share and has a dividend yield of 0.41%, as of April 17. Its dividend growth spans 32 years.